Next Article in Journal
Theophylline-7β-d-Ribofuranoside (Theonosine), a New Theophylline Metabolite Generated in Human and Animal Lung Tissue
Next Article in Special Issue
Efficient Transdermal Delivery of Alendronate, a Nitrogen-Containing Bisphosphonate, Using Tip-Loaded Self-Dissolving Microneedle Arrays for the Treatment of Osteoporosis
Previous Article in Journal / Special Issue
A Possible Percutaneous Penetration Pathway That Should Be Considered
Article Menu
Issue 3 (September) cover image

Export Article

Open AccessFeature PaperArticle
Pharmaceutics 2017, 9(3), 27; doi:10.3390/pharmaceutics9030027

Development of Novel Faster-Dissolving Microneedle Patches for Transcutaneous Vaccine Delivery

1
Project for Vaccine and Immune Regulation, Graduate School of Pharmaceutical Sciences, Osaka University, 1-6 Yamadaoka, Suita, Osaka 565-0871, Japan
2
Laboratory of Biotechnology and Therapeutics, Graduate School of Pharmaceutical Sciences, Osaka University, 1-6 Yamadaoka, Suita, Osaka 565-0871, Japan
3
Department of Dermatology, Nara Medical University, 840 Shin-cho, Kashihara, Nara 634-8522, Japan
4
CosMED Pharmaceutical Co. Ltd., 32 Higashikujokawanishi-cho, Minami-ku, Kyoto 601-8014, Japan
5
Laboratory of Vaccine and Immune Regulation, Graduate School of Pharmaceutical Sciences, Osaka University, 1-6 Yamadaoka, Suita, Osaka 565-0871, Japan
These authors contribute equally to this work.
*
Author to whom correspondence should be addressed.
Received: 30 June 2017 / Revised: 24 July 2017 / Accepted: 27 July 2017 / Published: 3 August 2017
(This article belongs to the Special Issue Recent Technology of Transdermal and Topical Drug Delivery)
View Full-Text   |   Download PDF [3904 KB, uploaded 3 August 2017]   |  

Abstract

Microneedle (MN) patches are promising for transcutaneous vaccination because they enable vaccine antigens to physically penetrate the stratum corneum via low-invasive skin puncturing, and to be effectively delivered to antigen-presenting cells in the skin. In second-generation MN patches, the dissolving MNs release the loaded vaccine antigen into the skin. To shorten skin application time for clinical practice, this study aims to develop novel faster-dissolving MNs. We designed two types of MNs made from a single thickening agent, carboxymethylcellulose (CMC) or hyaluronan (HN). Both CMC-MN and HN-MN completely dissolved in rat skin after a 5-min application. In pre-clinical studies, both MNs could demonstrably increase antigen-specific IgG levels after vaccination and prolong antigen deposition compared with conventional injections, and deliver antigens into resected human dermal tissue. In clinical research, we demonstrated that both MNs could reliably and safely puncture human skin without any significant skin irritation from transepidermal water loss measurements and ICDRG (International Contact Dermatitis Research Group) evaluation results. View Full-Text
Keywords: transcutaneous vaccine; faster-dissolving microneedle; carboxymethylcellulose; hyaluronan; clinical research; microneedle-dissolution kinetics in the skin; microneedle failure force transcutaneous vaccine; faster-dissolving microneedle; carboxymethylcellulose; hyaluronan; clinical research; microneedle-dissolution kinetics in the skin; microneedle failure force
Figures

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).

Scifeed alert for new publications

Never miss any articles matching your research from any publisher
  • Get alerts for new papers matching your research
  • Find out the new papers from selected authors
  • Updated daily for 49'000+ journals and 6000+ publishers
  • Define your Scifeed now

SciFeed Share & Cite This Article

MDPI and ACS Style

Ono, A.; Ito, S.; Sakagami, S.; Asada, H.; Saito, M.; Quan, Y.-S.; Kamiyama, F.; Hirobe, S.; Okada, N. Development of Novel Faster-Dissolving Microneedle Patches for Transcutaneous Vaccine Delivery. Pharmaceutics 2017, 9, 27.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Pharmaceutics EISSN 1999-4923 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top